Cullinan Therapeutics, Inc. (CGEM) vs Solid Biosciences Inc. (SLDB)

Cullinan Therapeutics, Inc. and Solid Biosciences Inc. are both Biotechnology companies. Cullinan Therapeutics, Inc. and Solid Biosciences Inc. are of similar size ($695.0M and $662.7M). Across the 8 metrics below, Solid Biosciences Inc. leads on 5 and Cullinan Therapeutics, Inc. on 3.

Valuation

Metric CGEM SLDB Biotechnology median
P/E n/m n/m 10.60
P/S n/m 88.22 9.40
P/B 2.17 2.90 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 57.17 9.02
Earnings yield (27.34%) (27.20%) (32.88%)
Free cash flow yield (22.84%) (20.18%) (23.13%)

Profitability

Metric CGEM SLDB Biotechnology median
Gross margin — 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (50.30%) (76.87%) (51.96%)
Return on assets (46.30%) (64.86%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CGEM SLDB Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (20.86%) 34.97% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CGEM SLDB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.42 11.99 4.97
Net debt to EBITDA 1.57 1.05 1.01

Dividend

Metric CGEM SLDB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CGEM SLDB Biotechnology median
Market cap 695.03m 662.65m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack